JP2013515079A - 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法 - Google Patents

低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法 Download PDF

Info

Publication number
JP2013515079A
JP2013515079A JP2012546164A JP2012546164A JP2013515079A JP 2013515079 A JP2013515079 A JP 2013515079A JP 2012546164 A JP2012546164 A JP 2012546164A JP 2012546164 A JP2012546164 A JP 2012546164A JP 2013515079 A JP2013515079 A JP 2013515079A
Authority
JP
Japan
Prior art keywords
antibody
region
pcrv
patient
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012546164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515079A5 (enExample
Inventor
ジェフリー ティー． ヤラントン
Original Assignee
カロバイオス ファーマシューティカルズ インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カロバイオス ファーマシューティカルズ インコーポレイティッド filed Critical カロバイオス ファーマシューティカルズ インコーポレイティッド
Publication of JP2013515079A publication Critical patent/JP2013515079A/ja
Publication of JP2013515079A5 publication Critical patent/JP2013515079A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012546164A 2009-12-22 2010-12-21 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法 Pending JP2013515079A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28897709P 2009-12-22 2009-12-22
US61/288,977 2009-12-22
PCT/US2010/061636 WO2011087799A1 (en) 2009-12-22 2010-12-21 A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection

Publications (2)

Publication Number Publication Date
JP2013515079A true JP2013515079A (ja) 2013-05-02
JP2013515079A5 JP2013515079A5 (enExample) 2014-05-29

Family

ID=44224810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012546164A Pending JP2013515079A (ja) 2009-12-22 2010-12-21 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法

Country Status (5)

Country Link
US (1) US8642039B2 (enExample)
EP (1) EP2515935A4 (enExample)
JP (1) JP2013515079A (enExample)
CA (1) CA2784033A1 (enExample)
WO (1) WO2011087799A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519768A (ja) * 2014-06-19 2017-07-20 メディミューン，エルエルシー 多細菌性感染の治療

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667791A1 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US20100310665A1 (en) * 2007-10-25 2010-12-09 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US20090263495A1 (en) * 2007-10-25 2009-10-22 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
KR20130114581A (ko) 2010-05-07 2013-10-18 레발레시오 코퍼레이션 생리적 수행능력 및 회복 시간의 향상을 위한 조성물 및 방법
BR112013003110A2 (pt) 2010-08-12 2016-06-28 Revalesio Corp composições e métodos para tratamento de taupatia
CA2838211C (en) 2011-06-10 2023-08-01 Medimmmune Limited Anti-pseudomonas psl binding molecules and uses thereof
HUE050985T2 (hu) 2011-11-07 2021-01-28 Medimmune Ltd Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
RU2759949C2 (ru) 2015-05-01 2021-11-19 Инхибркс, Инк. Молекулы, нацеленные на систему секреции типа iii
TW202100549A (zh) 2019-03-13 2021-01-01 美商麥迪紐有限責任公司 降低金黃色葡萄球菌在定殖的患者中之感染
CN118620074A (zh) * 2020-06-01 2024-09-10 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228384A1 (en) * 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
JP2007538075A (ja) * 2004-05-17 2007-12-27 コラス・フアーマ・インコーポレイテツド 細菌性呼吸器感染症を治療するためのエーロゾル化されたホスホマイシン／アミノグリコシド組合せ
WO2008063341A2 (en) * 2006-10-24 2008-05-29 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
WO2009042187A1 (en) * 2007-09-25 2009-04-02 Nektar Therapeutics Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
WO2009073631A2 (en) * 2007-11-30 2009-06-11 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033872A2 (en) * 1998-11-25 2000-06-15 Mcw Research Foundation, Inc. Method of and compositions for immunization with the pseudomonas v antigen
CA2751433A1 (en) 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007538075A (ja) * 2004-05-17 2007-12-27 コラス・フアーマ・インコーポレイテツド 細菌性呼吸器感染症を治療するためのエーロゾル化されたホスホマイシン／アミノグリコシド組合せ
US20060228384A1 (en) * 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
WO2008063341A2 (en) * 2006-10-24 2008-05-29 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
WO2009042187A1 (en) * 2007-09-25 2009-04-02 Nektar Therapeutics Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
WO2009073631A2 (en) * 2007-11-30 2009-06-11 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014052572; Ｊ．　Ｂｏｎｅ　Ｊｏｉｎｔ　Ｓｕｒｇ．　Ａｍ． Ｖｏｌ．８３-Ａ，Ｎｏ．６, 2001, ｐ．８５５-８６１ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519768A (ja) * 2014-06-19 2017-07-20 メディミューン，エルエルシー 多細菌性感染の治療
JP2021063090A (ja) * 2014-06-19 2021-04-22 メディミューン，エルエルシー 多細菌性感染の治療

Also Published As

Publication number Publication date
US20110165172A1 (en) 2011-07-07
EP2515935A4 (en) 2013-08-28
WO2011087799A1 (en) 2011-07-21
US8642039B2 (en) 2014-02-04
CA2784033A1 (en) 2011-07-21
EP2515935A1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
US8642039B2 (en) Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infection
AU2008333985B2 (en) Antibodies to the PcrV antigen of pseudomonas aeruginosa
TWI719938B (zh) 多重細菌感染之治療
US8653242B2 (en) Therapeutic antibodies against flagellated Pseudomonas aeruginosa
JP2011505381A5 (enExample)
EP2860191B1 (en) Human monoclonal antibody against S. aureus derived alpha-toxin and its use in treating or preventing abscess formation
JP2022163050A (ja) 院内肺炎を予防または治療する方法
WO2021052461A1 (zh) 抗α-溶血素的抗体及其应用
KR20170136637A (ko) 항-스타필로코커스 아우레우스 항체 배합 제제
US20100272736A1 (en) Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
WO2024020236A2 (en) Monoclonal antibodies that interfere with iron uptake

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150511